• Lactobacillus gasseri Modulates Colitis via NR1I3-E-cadherin

  2026-05-20

  Qian et al. (2024) demonstrate that Lactobacillus gasseri ATCC33323 alleviates DSS-induced colitis in mice by regulating E-cadherin expression through the NR1I3 pathway. This mechanistic insight clarifies how targeted probiotic intervention can reinforce the intestinal barrier, offering a foundation for novel IBD therapies.

• 7-AAD Cell Viability Assay Kit: Precision in Apoptosis and N

  2026-05-19

  Explore the advanced science behind the 7-AAD Cell Viability Assay Kit for apoptosis and necrosis detection. This article unpacks the unique spectral and mechanistic advantages of 7-amino actinomycin D assays, integrating new structural insights from CAR-T research for informed experimental design.

• Omeprazole (A2845): Protocols for H+,K+-ATPase Inhibition Re

  2026-05-19

  Omeprazole (SKU A2845) is a potent H+,K+-ATPase inhibitor designed for controlled manipulation of gastric acid secretion in preclinical and mechanistic research settings. It is best suited for in vitro and ex vivo models of gastric acid-related disorders and antiulcer activity studies, but is not intended for diagnostic, therapeutic, or prolonged storage applications.

• Perphenazine: Dopamine D2 Receptor Antagonist in Advanced Re

  2026-05-18

  Perphenazine, a potent dopamine D2 receptor antagonist, enables robust modeling in neuropharmacology, mitochondria-mediated cell death, and host-directed antibacterial research. This article breaks down experimental workflows, protocol refinements, and troubleshooting strategies leveraging APExBIO’s high-purity Perphenazine for reproducible, high-impact studies.

• Screening MMV Compounds for Activity Against MDR Bacteria an

  2026-05-18

  This study systematically evaluated the MMV Pandemic Response Box for agents active against multidrug-resistant Acinetobacter baumannii, Pseudomonas aeruginosa, and key fungal pathogens. The findings highlight several compounds with bactericidal or fungicidal activity in vitro, informing future drug development and antibacterial assay design.

• Otilonium Bromide: Antimuscarinic Agent for Cholinergic Rese

  2026-05-17

  Otilonium Bromide is a high-purity antimuscarinic agent used to inhibit acetylcholine receptors in neuroscience and smooth muscle research. Its efficacy in modulating cholinergic signaling pathways is well-documented, making it a preferred tool for in vitro experimental protocols. APExBIO supplies Otilonium Bromide (SKU: B1607) in powder and solution formats for reliable, reproducible results.

• Methylation, Folate Antagonists, and Neurological Disorders:

  2026-05-16

  This review synthesizes the biochemical and clinical intersections of methylation, folate metabolism, and neuropsychiatric disease, highlighting the unique role of S-adenosylmethionine (SAMe) and the consequences of its disruption. The findings underscore how deficiencies in folate or vitamin B12 can alter CNS methylation, with direct relevance for research into folate antagonists such as methotrexate.

• Novobiocin: Advanced Assay Guidance and Biotechnological Ins

  2026-05-15

  Explore Novobiocin, a potent aminocoumarin antibiotic, through the lens of advanced assay design and biotechnological innovation. This article delivers in-depth, evidence-based guidance for researchers seeking optimal use and scientific context beyond standard protocols.

• Balsalazide Disodium Dihydrate: Radiotracer Innovation for U

  2026-05-15

  Explore the advanced applications of Balsalazide Disodium Dihydrate as a selective radiotracer and anti-inflammatory agent in ulcerative colitis research. This article unveils unique insights into radioiodination techniques, protocol parameters, and translational opportunities, elevating your inflammation research with APExBIO's high-purity compound.

• Transmission Dynamics of Carbapenemase Genes in CREC in Chin

  2026-05-14

  This study provides a granular analysis of carbapenemase-encoding gene (CEG) prevalence and transmission in carbapenem-resistant Enterobacter cloacae (CREC) from eight hospitals in Guangdong during the COVID-19 pandemic. The findings clarify the genomic localization, transferability, and epidemiology of key CEGs, with direct implications for understanding multidrug resistance and guiding future antimicrobial research.

• Danazol in Endocrine Modeling: Innovations Beyond Puberty Re

  2026-05-14

  Explore Danazol’s role as a potent modulator of steroidogenesis and the HPG axis. This article delivers a unique, protocol-driven analysis for advanced prostate cancer and precocious puberty models, highlighting new assay insights and APExBIO’s high-purity Danazol advantages.

• GPX4-Mediated Glutathione Consumption Drives Platinum Resist

  2026-05-13

  This study elucidates how brain-metastatic lung cancer cells develop pronounced resistance to platinum chemotherapy by upregulating GPX4 and GSTM1, resulting in high glutathione consumption and ferroptosis suppression. The authors identify Wnt/NR2F2 signaling as a key regulator of GPX4 expression, offering mechanistic insight and potential avenues for overcoming chemoresistance in brain metastases.

• Translating Dual Luciferase Insight to Oncology: ZNF263 and

  2026-05-13

  This thought-leadership article, designed for translational researchers, explores how the Dual Luciferase Reporter Gene System (SKU: K1136) from APExBIO advances our mechanistic understanding and experimental rigor in gene expression regulation—exemplified by recent findings on ZNF263-driven autophagy in intrahepatic cholangiocarcinoma (ICC). The article contextualizes these advances within the competitive assay landscape, dissects biological rationale, and offers actionable protocol guidance, while articulating how this resource moves beyond conventional product overviews.

• JAK Inhibitors and Endothelial Dysfunction: Comparative Vasc

  2026-05-12

  This study systematically compares the vascular effects of several JAK inhibitors, including tofacitinib citrate (CP-690550 citrate), on human endothelial cells exposed to inflammatory cytokines. The findings clarify both the anti-inflammatory potential and pro-thrombotic risks across JAK inhibitor classes, with practical implications for immune regulation and inflammatory disorder research.

• Refining In Vitro Cancer Drug Evaluation: Insights from Schw

  2026-05-12

  Schwartz et al. introduce a nuanced framework for in vitro assessment of anti-cancer drug responses, distinguishing between relative viability and fractional viability to better capture both proliferative arrest and cell death. This approach clarifies the interpretation of drug effects in cancer biology research, facilitating more reliable assay design and data analysis.

15597 records 1/1040 page Next 12345 下5页 Last page